TRGN.F Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.62 |
| 52 Week High | €2.10 |
| 52 Week Low | €1.62 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -23.94% |
| 5 Year Change | -51.20% |
| Change since IPO | -87.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRGN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how TRGN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TRGN.F performed against the US Market.
Price Volatility
| TRGN.F volatility | |
|---|---|
| TRGN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRGN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TRGN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 146 | Alessandro Riva | www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TRGN.F fundamental statistics | |
|---|---|
| Market cap | US$149.78m |
| Earnings (TTM) | -US$36.50m |
| Revenue (TTM) | US$9.73m |
15.4x
P/S Ratio-4.1x
P/E RatioIs TRGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRGN.F income statement (TTM) | |
|---|---|
| Revenue | €8.91m |
| Cost of Revenue | €30.76m |
| Gross Profit | -€21.86m |
| Other Expenses | €11.57m |
| Earnings | -€33.43m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -245.38% |
| Net Profit Margin | -375.29% |
| Debt/Equity Ratio | 35.7% |
How did TRGN.F perform over the long term?
See historical performance and comparison